Groupe Hospitalier De La Region De Mulhouse Et Sud Alsace — Clinical Trial Site

79 Registered trials

46 Currently recruiting

Organisation

Groupe Hospitalier De La Region De Mulhouse Et Sud Alsace

Location

Mulhouse, France

Identifier

ORG-100040766

Address

87 Avenue D Altkirch, 68100, France

Departments

#5019: Hématologie Clinique
2306: Service de Pneumologie
Département de Cardiologie
Department of Hematology
GASTRO ENTEROLOGY
Haematology
Hématologie
Hematology
Hematology Department
Hépato Gastro Entérologie
intensive care
Intensive Care Unit
Internal Medicine
Laboratoire de microbiologie
Médecine interne et immunologie clinique
Nephrology
Oncologia
Oncologie
oncologie médicale
ONCOLOGY
Pneumologie
PneumologY
Réanimation
Service d'Hématologie
Service d'Hematologie Clinique
Service d’Endocrinologie
Service d’Hématologie
Service d’Hématologie Clinique
Service de Dermatologie
Service de Médicine interne et immunologie clinique
Service de Médicine interne et immunologie clinique
Service de Néphrologie
service de pneumologie
Service de soin intentifs
Service de soins intensifs
Service Pneumologie

Clinical trials at this site (79)

Search interface

Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Advanced Non-Small Cell Lung Cancer 10 2021-03-17
GRAALL2014 Recruiting

2024-516103-16-00 Acute Lymphoblastic Leukemia (ALL) in younger adults (1 4 2015-12-04
Phase 3 trial aimed at improving the overall survival of AML in adults aged 18 to 60 by comparing high-dose idarubicin with daunorubicin at … Ended

2024-516873-57-00 Acute myeloid leukemia in adults aged 18 to 60 10 2026-01-13
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended

2024-512998-27-00 Non-Small Cell Lung Cancer 5 2025-02-21
A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome Ended

2023-503923-24-00 Sjögren’s Syndrome With Moderate-toSevere Symptom State 5 2024-07-22
A Phase III Study to assess efficacy, safety, and tolerability of Zibotentan combined with Dapagliflozin, compared to Dapagliflozin, in pati… Ended

2023-504124-26-00 Chronic Kidney Disease and High Proteinuria 5 2024-04-04
A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either… Ended

2023-503357-35-00 Non-small Cell Lung Cancer (NSCLC) 4 2024-03-20
A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB… Ended

2023-506139-13-00 Treatment naïve patients with MF 5 2024-01-04
IFCT-2201 ADAPTABLE A study evaluating the combination of paclitaxel-bevacizumab ± atezolizumab in patients with advanced lung cancer progre… Ended

2022-502103-30-00 advanced non-squamous non-small cell lung cancer 4 2023-04-25
IFCT-2101 MASTERPROTOCOL ALK : Study of safety and efficacy of brigatinib and carboplatin-pemetrexed combination therapy or brigatinib monot… Ended

2023-510387-13-00 advanced ALK-positive non-small cell lung cancer 4 2022-05-18
FILOCLL14 - STAIR : "Open-label, phase 2 study investigating the STop and restart Acalabrutinib In fRrail patients with previously untreated… Ended

2024-513936-80-00 elderly patients (> 70 years) with CLL or SLL 4 2021-11-12
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) Ended

2024-512028-12-00 Advanced ROS1-positive non-small cell lung cancer 4 2021-03-19
KILT - A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERA… Ended

2024-513252-15-00 IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL 4 2021-01-28
Encorafenib in combination with Binimetinib in Patients with BRAFV600E mutant metastatic Lung Cancer Ended

2024-515944-22-00 BRAFV600E-mutant metastatic Non-small Cell Lung Cancer 4 2021-01-19
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended

2023-507263-19-00 Advanced Non-Small Cell Lung Cancer 5 2020-12-23
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients with Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung… Ended

2024-511185-37-00 Completely resected stage I or IIA non-squamous non-sma 6 2020-11-03
A Phase 3 Study Comparing Lenalidomide and Daratumumab Subcutaneous Injection (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Su… Ended

2024-514088-25-00 Multiple Myeloma 5 2019-10-07
Phase III randomized trial of atezolizumab in elderly patients with advanced Non-Small-Cell Lung Cancer and receiving monthly carboplatin wi… Ended

2024-515946-17-00 Non Small Cell Lung Cancer 5 2019-07-22
Study of the efficacy of treatment with AG-120 in patients with Myelodysplastic Syndrome and mutation IDH1 Ended

2024-515352-20-00 myelodysplastic syndrome with IDH1 mutated 4 2019-03-20
Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio… Ended

2022-502832-37-00 Acute myeloid leukemia 5 2019-03-01
study of the efficacy of treatment with AG-221 in patients with myelodysplastic syndrome and mutation IDH2 Ended

2024-513858-29-01 myelodysplastic syndrome with IDH2 mutated 4 2019-02-06
Maintaining or Stopping immunosuppressive Therapy in patients with ANCA vasculitis and End-stage Renal disease: a prospective, multicenter, … Ended

2024-512470-10-00 End-stage Renal disease 11 2018-02-02
A study evaluating the effects of GLPG3667 given as oral treatment in adults with active systemic lupus erythematosus. Ended

2023-503183-16-00 Systemic Lupus Erythematosus 4 2024-01-16
A Phase 2 study (NEPTUNE-17) to evaluate efficacy and safety of GSK3858279 in DPNP. Ended

2022-502313-28-00 Diabetic Peripheral Neuropathic Pain 4 2023-12-14